Palmoplantar PsoriasisNCT07626697
Dermoscopy and UVFD in Differentiating Palmoplantar Psoriasis and Palmoplantar Eczema
An observational study of Palmoplantar Psoriasis and Eczema, run by Istanbul Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Palmoplantar psoriasis and palmoplantar eczema are chronic inflammatory skin diseases that may show similar findings on the palms and soles, such as redness, scaling, thickening of the skin, fissures, itching, and burning. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Palmoplantar Psoriasis, Eczema
- How many people
- 81 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Nov 2025to 31 Jul 2026
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: A total of 81 adult patients aged 18 years and older with clinically and/or histopathologically confirmed palmoplantar plaque psoriasis or palmoplantar eczema were included. Participants were recruited from the dermatology outpatient clinic of a tertiary care training and research hospital.
Who may be able to join
- Age 18 years or older.
- Clinical diagnosis of palmoplantar psoriasis or palmoplantar eczema involving the palms and/or soles.
- For the palmoplantar psoriasis group: presence of sharply demarcated erythematous and scaly plaques on the palms and/or soles, with diagnosis confirmed clinically and/or histopathologically.
- In clinically uncertain palmoplantar psoriasis cases, at least one supporting feature such as psoriatic lesions outside the palmoplantar area, psoriatic nail involvement, psoriatic arthritis, personal history of psoriasis, or family history of psoriasis.
- For the palmoplantar eczema group: presence of chronic or recurrent palmoplantar eczema with hyperkeratotic and/or fissured palmoplantar plaques, with diagnosis confirmed clinically and/or histopathologically.
- Ability and willingness to provide written informed consent.
Who cannot join
- Age younger than 18 years.
- Presence of another palmoplantar dermatosis that may interfere with the diagnosis of palmoplantar psoriasis or palmoplantar eczema.
- Histopathological findings inconsistent with the clinical diagnosis, when histopathological examination was performed.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Istanbul Training and Research Hospital
Istanbul, Istanbul, 34000
About this study
Official title: Comparative Evaluation of Polarized Dermoscopy and Ultraviolet-Induced Fluorescence Dermoscopy in the Differential Diagnosis of Palmoplantar Psoriasis and Palmoplantar Eczema
Palmoplantar psoriasis and palmoplantar eczema are chronic inflammatory skin diseases that may show similar findings on the palms and soles, such as redness, scaling, thickening of the skin, fissures, itching, and burning. Because these conditions can look alike, distinguishing between them in routine clinical practice may be difficult.
This prospective, single-center observational study was designed to compare polarized dermoscopic and ultraviolet-induced fluorescence dermoscopic (UVFD) findings in adult patients with palmoplantar psoriasis and palmoplantar eczema. A total of 81 patients aged 18 years and older were included: 41 patients with clinically and/or histopathologically confirmed palmoplantar plaque psoriasis and 40 patients with palmoplantar eczema.
Dermoscopic and UVFD images were evaluated to identify vascular, scaling, surface, and fluorescence-related features that may help differentiate palmoplantar psoriasis from palmoplantar eczema. The study aims to assess whether these non-invasive imaging methods can provide additional diagnostic clues to support clinical evaluation.
Read the detailed description
This prospective, single-center, observational comparative study was designed to evaluate polarized dermoscopic and ultraviolet-induced fluorescence dermoscopic (UVFD) findings in the differential diagnosis of palmoplantar psoriasis and palmoplantar eczema.
Adult patients aged 18 years and older with clinically and/or histopathologically confirmed palmoplantar plaque psoriasis or palmoplantar eczema were enrolled. Patients with recent topical or systemic treatment, positive fungal examination, palmoplantar pustulosis, other confounding palmoplantar dermatoses, malignancy or immunosuppressive conditions, pregnancy, lactation, non-specific histopathological findings, or histopathological findings inconsistent with the clinical diagnosis were excluded.
Demographic and clinical characteristics, lesion localization, symptom profile, relevant dermatological history, nail involvement, and disease severity parameters were recorded. Standardized polarized dermoscopic and UVFD images were obtained using a handheld dermoscope (DermLite DL5, 3Gen Inc., San Juan Capistrano, CA, USA). Imaging was performed under standardized conditions, and predefined dermoscopic and UVFD parameters relevant to inflammatory palmoplantar dermatoses were systematically evaluated.
In polarized dermoscopy, vascular morphology and distribution, scale color and distribution, background color, yellow-brown globules, yellow-orange structureless areas, yellow-orange crusts, and hemorrhage within scales were assessed. In UVFD, scale distribution, scale pattern, dominant fluorescence color, additional fluorescence color, and white-yellow fluorescent foci were evaluated. Image assessments were performed by independent dermatologists blinded to the clinical diagnosis.
The main objective of the study is to compare polarized dermoscopic and UVFD findings between palmoplantar psoriasis and palmoplantar eczema and to identify features that may support the clinical differentiation of these overlapping palmoplantar dermatoses. The study does not assign any treatment or intervention; all imaging procedures are non-invasive and performed for observational diagnostic evaluation.
- Conditions
- Palmoplantar Psoriasis, Eczema
- Keywords
- Palmoplantar eczema, Palmoplantar psoriasis, Dermoscopy, Ultraviolet dermoscopy, UV dermoscopy, Differential diagnosis
- Medical subject headings
- Eczema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Palmoplantar Psoriasis | Patients with clinically and/or histopathologically confirmed palmoplantar psoriasis | |
| Palmoplantar Eczema | Patients with clinically and/or histopathologically confirmed palmoplantar eczema |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Findings on the Predefined Polarized Dermoscopic Feature Checklist Assessed Using DermLite DL5
Name of measurement: Predefined Polarized Dermoscopic Feature Checklist. Measurement tool: standardized polarized dermoscopic images obtained with a DermLite DL5 handheld dermoscope. Unit of measure: percentage of participants (%).
Standardized polarized dermoscopic images will be assessed by blinded independent dermatologists using the checklist. The checklist includes vascular morphology, vascular distribution, scale color, scale distribution, background color, yellow-brown globules, yellow-orange structureless areas, yellow-orange crusts, and hemorrhage within scales. The percentage of participants with each finding will be reported separately for the palmoplantar psoriasis and palmoplantar eczema groups.
Measured: At baseline / single study visit
Percentage of Participants With Each Predefined Ultraviolet-Induced Fluorescence Dermoscopy Feature Assessed by DermLite DL5
Unit of measure: percentage of participants (%). Measurement tool: standardized ultraviolet-induced fluorescence dermoscopy (UVFD) images obtained with a DermLite DL5 handheld dermoscope and assessed by blinded independent dermatologists using a predefined UVFD feature checklist. The checklist includes UVFD scale distribution, UVFD scale pattern, dominant fluorescence color, additional fluorescence color, and white-yellow fluorescent foci. The percentage of participants with each feature will be reported and compared between the palmoplantar psoriasis and palmoplantar eczema groups.
Measured: At baseline / single study visit
Secondary outcomes (2)
Cohen's Kappa Coefficient for Interobserver Agreement in Binary and Nominal Dermoscopic and UVFD Feature Assessment
Name of measurement: Cohen's kappa coefficient for interobserver agreement. Measurement tool: blinded independent assessment of standardized polarized dermoscopic and ultraviolet fluorescence dermoscopic images using predefined feature checklists. Unit of measure: Cohen's kappa coefficient.
Two blinded independent dermatologists will assess standardized images using predefined feature checklists. Cohen's kappa coefficient will be calculated separately for binary and nominal categorical checklist findings to evaluate interobserver agreement.
Measured: At baseline / single study visit
Quadratic Weighted Kappa Coefficient for Interobserver Agreement in Ordinal Dermoscopic and UVFD Feature Assessment
Name of measurement: quadratic weighted kappa coefficient for interobserver agreement. Measurement tool: blinded independent assessment of standardized polarized dermoscopic and ultraviolet fluorescence dermoscopic images using predefined feature checklists. Unit of measure: quadratic weighted kappa coefficient.
Two blinded independent dermatologists will assess standardized images using predefined feature checklists. Quadratic weighted kappa coefficient will be calculated separately for ordinal checklist findings to evaluate interobserver agreement.
Measured: At baseline / single study visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Jun 2026
- Study start1 Nov 2025
- Primary completion20 Apr 2026
- Study completion31 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Palmoplantar PsoriasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 81 participants (actual)
Sponsor and investigators
- Lead sponsor
- Istanbul Training and Research Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Didem Kacan, Istanbul Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07626697
- Sponsor's protocol ID
- 2011-KAEK-50-263
- Status last verified
- May 2026
- First submitted
- 8 May 2026
- Last updated
- 4 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No